Dash Dhanak PhD, BSc

Dash Dhanak, Ph.D. leads an organization responsible for supporting and enabling the discovery and early development of novel small molecule therapeutics.

Prior to joining Janssen, Dash spent 25 years at GlaxoSmithKline (GSK), most recently as Vice President and Head of the Cancer Epigenetics Discovery Performance Unit. Dash received a B.S. in Chemistry from the University Of Manchester Institute of Science and Technology and a Ph.D. from the University of London, both in the United Kingdom. He subsequently carried out postdoctoral research in natural product synthesis at Northwestern University in Illinois, United States prior to joining GSK. In addition, he has published extensively on a variety of drug discovery topics.

Dash is a member of the American Association of Cancer Research Epigenome Task Force, has participated in the American Chemical Society Pharma Leaders Forum, as well as the American Cancer Society Peer Review Committee on Cancer Drug Development and the Multiple Myeloma Research Foundation Peer Review Committee. In addition, he has been an invited speaker at major scientific conferences.